NanoViricides, Inc. Raises Approximately $7.5 Million Upon Exercise...

... This strong cash position now enables us to purchase the new modern R&D Lab and cGMP Clinical Production facility in Shelton, CT, without affecting any of our developmental programs including FluCidea and DengueCidea , or any of our R&D programs, ...



via Shelton Newswire http://ift.tt/1ru6DoJ